Skip to main content
OpenTrials
Completed

NCT Number: NCT03148340

Volumetric Integral Phase-shift Spectroscopy for Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology

The purpose of this study is to assess the ability of the Fluids Monitor to detect hemispheric bioimpedance asymmetry associated with acute brain pathology in patients presenting with suspected Acute Ischemic Stroke (AIS).

Completed

Looking for future studies?

Notify Me

Key information

About this study

A prospective non-significant-risk (NSR) multi-site observational study. This study will examine up to 318 subjects undergoing evaluation for acute brain pathology who directly arrive at, or are transferred to, the participating sites.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Must be at least 18 years of age.
  • Being evaluated for acute ischemic stroke.
  • Able to safely wear the study device for up to 2 minutes per reading.
  • Have NIHSS performed before before study device monitoring.
  • Must be able to provide written Informed Consent (either self or via an LAR) at any point during the hospital stay, or if unable to provide such consent, must have permission granted by the governing IRB to enroll in the study (i.e., waiver of consent).

Exclusion criteria

  • Known or suspected traumatic brain injury, either closed or penetrating.
  • Contraindication to neuroimaging, such as a contrast allergy, or other condition that prohibits CT, MRI, and/or angiography.
  • Presence of any implanted electro-stimulating devices in the head and neck.
  • Presence of any large metallic craniofacial implants, such as bone fixation plates, mesh, et cetera. (Note that small metallic objects, such an aneurysm coils, are acceptable.)
  • Presence of an intracranial pressure monitor or any other similar sensor that may compromise the placement of the investigational device.
  • Under arrest or otherwise in custody.
  • Inability to wear the investigational device (skin lesions on scalp, previous intracranial surgeries, etc.).
  • Pregnant or nursing.
  • Any other condition, which in the judgment of the PI would prevent the patient from completing the study or tolerating monitoring sessions and brain imaging, such as mental illness, severe agitation, or hemodynamic instability.

Treatment and study plan

VIPS Monitoring

Diagnostic Test

Bioimpedance asymmetry

Other names: CMS

Primary outcomes

  1. Hemispheric bioimpedance asymmetry detection

    Time frame: At the time of VIPS monitoring - day 0

    The primary outcome will be the device's ability to detect hemispheric bioimpedance asymmetry associated with acute brain pathology in a population of patients presenting with symptoms consistent with AIS

Sponsors and collaborators

Lead sponsor

Cerebrotech Medical Systems, Inc.

Industry

Registry information

Official study title

VITAL: Volumetric Integral Phase-shift Spectroscopy (VIPS) for the Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology

Acronym: VITAL

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
May 11, 2017
Registry last updated
Dec 12, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.